Eyebright Medical(SH:688050)2021-10-27 16:00Financial Performance - Revenue for Q3 2021 reached ¥118,609,875.87, an increase of 52.18% year-over-year, and a year-to-date revenue of ¥324,897,389.11, up 78.99% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥48,863,722.01, a 57.01% increase year-over-year, with a year-to-date net profit of ¥140,312,560.71, reflecting a growth of 104.36%[3] - Basic earnings per share for Q3 2021 was ¥0.46, a 43.75% increase year-over-year, with diluted earnings per share also at ¥0.46[4] - Total operating revenue for the first three quarters of 2021 reached ¥324,897,389.11, a significant increase from ¥181,518,385.23 in the same period of 2020, representing an increase of approximately 79%[18] - Net profit for the third quarter of 2021 was ¥138,732,951.68, compared to ¥68,170,724.40 in the same quarter of 2020, reflecting an increase of about 103%[19] - The total comprehensive income for the third quarter of 2021 was ¥139,328,886.68, compared to ¥68,170,724.40 in the same quarter of 2020, indicating an increase of about 104%[20] Research and Development - R&D expenses totaled ¥18,475,009.63 for the quarter, representing an increase of 89.09%, and accounted for 15.58% of revenue, up 3.04 percentage points[4] - Total R&D investment for the current reporting period was 89.09 million RMB, driven by an increase in R&D projects and accelerated project development[9] - Total R&D investment from the beginning of the year to the reporting period was 94.68 million RMB, reflecting ongoing investment in innovation[9] - Research and development expenses for the third quarter of 2021 were ¥36,492,905.01, compared to ¥18,601,287.94 in the same quarter of 2020, marking an increase of approximately 96%[18] Cash Flow and Assets - The company reported a net cash flow from operating activities of ¥145,112,101.02 year-to-date, an increase of 182.06% compared to the same period last year[4] - Cash inflow from operating activities totaled RMB 360,490,617.10, a significant increase from RMB 175,103,393.40 in the same period last year, representing a growth of 105.5%[22] - Net cash flow from operating activities reached RMB 145,112,101.02, compared to RMB 51,448,068.30 in the previous year, marking an increase of 182.5%[22] - Total assets as of the end of the reporting period were ¥1,906,704,705.53, a 16.37% increase from the end of the previous year[4] - Current assets totaled 1,163.23 million RMB, compared to 1,146.17 million RMB in the previous year[15] - The company reported cash and cash equivalents of 490.20 million RMB, down from 536.84 million RMB in the previous year[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 12,357, with the largest shareholder holding 12.93% of shares[10] - The top ten shareholders collectively hold significant stakes, with the largest shareholder owning 13,594,779 shares[10] - The company's total equity attributable to shareholders reached ¥1,637,329,676.20, an increase from ¥1,518,102,671.45 year-over-year, which is about a 7.85% increase[17] Liabilities and Equity - The total liabilities as of the end of the third quarter of 2021 amounted to ¥213,584,767.46, up from ¥90,894,611.56 in the previous year, indicating a growth of approximately 135%[18] - Total liabilities amounted to ¥90,894,611.56, with current liabilities at ¥77,091,869.54 and non-current liabilities at ¥13,802,742.02[25] - The company reported an undistributed profit of ¥89,980,094.20 and a surplus reserve of ¥17,756,261.14[26] Future Outlook - The increase in revenue was primarily driven by strong sales growth in artificial lenses and orthokeratology lenses[8] - The company plans to continue expanding its market presence and investing in R&D to support future growth[8]